Share This Page
Drug Price Trends for NDC 72493-0103
✉ Email this page to a colleague
Average Pharmacy Cost for 72493-0103
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 72493-0103
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for Lurasidone Hydrochloride (NDC: 72493-0103)
Last updated: February 19, 2026
This report analyzes the market for lurasidone hydrochloride, specifically focusing on the product with National Drug Code (NDC) 72493-0103. It examines current market dynamics, competitive landscape, patent status, and projects future pricing trends.
What is Lurasidone Hydrochloride?
Lurasidone hydrochloride is an atypical antipsychotic medication prescribed for the treatment of schizophrenia and bipolar depression [1]. It functions by modulating the activity of dopamine and serotonin receptors in the brain. The efficacy and side effect profile of lurasidone hydrochloride place it within a competitive class of antipsychotic drugs.
What is the Current Market Size and Growth Trajectory for Lurasidone Hydrochloride?
The market for lurasidone hydrochloride has experienced substantial growth since its initial market entry. This growth is driven by the increasing prevalence of mental health disorders and the drug's established therapeutic profile.
- Market Size: Global sales for lurasidone hydrochloride have been robust. In 2023, the estimated global market value for lurasidone hydrochloride products approached $2.5 billion [2].
- Growth Rate: The market is projected to continue expanding at a compound annual growth rate (CAGR) of 4% to 6% over the next five years [2]. This projection accounts for both branded and generic competition.
- Key Drivers:
- Rising incidence of schizophrenia and bipolar disorder globally.
- Increased diagnosis rates and treatment adherence.
- Introduction of new formulations and delivery methods.
- Expanding access to healthcare in emerging markets.
Who are the Key Players in the Lurasidone Hydrochloride Market?
The market for lurasidone hydrochloride is characterized by the presence of both the innovator drug and a growing number of generic manufacturers.
- Innovator/Branded Product:
- Sunovion Pharmaceuticals (now Sumitomo Pharma Co., Ltd.): The originator of the lurasidone hydrochloride product, marketed as Latuda®.
- Generic Manufacturers: A significant number of pharmaceutical companies have entered the generic lurasidone hydrochloride market following patent expirations. Key players include, but are not limited to:
- Teva Pharmaceuticals
- Aurobindo Pharma
- Lupin Pharmaceuticals
- Dr. Reddy's Laboratories
- Torrent Pharmaceuticals
- Viatris Inc.
- Alembic Pharmaceuticals
- NDC 72493-0103: This specific NDC is associated with generic lurasidone hydrochloride products. The presence of multiple generic suppliers contributing to this NDC indicates a competitive landscape for this specific product code.
What is the Patent Landscape for Lurasidone Hydrochloride?
The patent protection for lurasidone hydrochloride has significantly influenced market dynamics, particularly the entry of generic competitors.
- Key Patents: The primary patents covering lurasidone hydrochloride, including its composition of matter and methods of use, have largely expired in major markets such as the United States and Europe.
- The U.S. composition of matter patent for lurasidone expired in 2018 [3].
- Subsequent patents related to specific formulations or methods of treatment have also reached their expiry or are nearing it [3].
- Impact of Patent Expiration: The expiration of key patents has opened the door for generic manufacturers to introduce their versions of lurasidone hydrochloride. This has led to increased competition and a subsequent decline in the average selling price (ASP) of the drug.
- Exclusivity Periods: Data suggests that the innovator product maintained market exclusivity until approximately 2018-2020 in key markets before significant generic penetration occurred.
What are the Current Pricing Trends for Lurasidone Hydrochloride (NDC: 72493-0103)?
The pricing of lurasidone hydrochloride, especially for generic formulations associated with NDC 72493-0103, has seen a downward trend due to increased competition.
- Branded vs. Generic Pricing: The average wholesale price (AWP) of branded Latuda® was significantly higher than generic lurasidone hydrochloride. Prior to widespread generic availability, the AWP for a 30-day supply could range from $400 to $700 [4].
- Generic Price Erosion: Following the launch of generic versions, the ASP for lurasidone hydrochloride has decreased substantially.
- The current AWP for generic lurasidone hydrochloride (across various manufacturers contributing to NDC 72493-0103) typically ranges from $50 to $150 for a 30-day supply, depending on dosage strength and quantity purchased [5].
- Pharmacy benefit managers (PBMs) and payers have negotiated significant discounts, leading to a market where list prices often do not reflect actual transaction prices.
- Factors Influencing Generic Pricing:
- Number of Generic Entrants: A higher number of competing generic manufacturers generally leads to more aggressive pricing.
- Manufacturing Costs: Economies of scale and efficient manufacturing processes can lower production costs for generics.
- Payer Negotiations: Large-volume purchasers and PBMs wield considerable power in negotiating lower prices.
- Formulation: While the core API is the same, minor differences in inactive ingredients or manufacturing processes can subtly influence pricing.
What are the Future Price Projections for Lurasidone Hydrochloride?
Future pricing for lurasidone hydrochloride is expected to be influenced by a complex interplay of market forces, including ongoing generic competition, potential new indications, and evolving healthcare policies.
- Projected Price Trend: The price of generic lurasidone hydrochloride (NDC: 72493-0103) is anticipated to remain relatively stable or experience a modest decline over the next 3 to 5 years. Significant price increases are unlikely unless new, patent-protected formulations emerge.
- Projected ASP Range (3-5 years): The ASP for a 30-day supply of generic lurasidone hydrochloride is projected to be between $45 and $130 [6].
- Factors Influencing Future Pricing:
- Sustained Generic Competition: The market is likely to remain crowded with generic manufacturers, perpetuating price competition.
- Market Penetration: As generic adoption matures, the rate of price decline may slow.
- Potential for New Indications or Formulations: While less likely for an established drug, the approval of lurasidone for new indications or the development of novel delivery systems (e.g., long-acting injectables) by the innovator or other companies could create new market segments with higher pricing potential. However, this would likely involve different NDCs and product lines.
- Regulatory Policies: Changes in drug pricing regulations, reimbursement policies, or market access strategies by governments and payers could impact pricing.
- Cost of Goods Sold (COGS): Fluctuations in the cost of raw materials and manufacturing will continue to play a role.
What is the Competitive Landscape for Lurasidone Hydrochloride?
Lurasidone hydrochloride competes within the broader antipsychotic market, which includes other atypical antipsychotics.
- Direct Competition:
- Other Atypical Antipsychotics: Lurasidone hydrochloride competes with drugs such as:
- Aripiprazole (Abilify®)
- Risperidone (Risperdal®)
- Olanzapine (Zyprexa®)
- Quetiapine (Seroquel®)
- Ziprasidone (Geodon®)
- Paliperidone (Invega®)
- Cariprazine (Vraylar®)
- Brexpiprazole (Rexulti®)
- Therapeutic Overlap: These drugs share similar indications for schizophrenia and bipolar disorder, leading to prescriber choice based on efficacy, tolerability, cost, and patient-specific factors.
- Other Atypical Antipsychotics: Lurasidone hydrochloride competes with drugs such as:
- Indirect Competition:
- Other Classes of Medications: Adjunctive therapies or alternative treatment modalities, although less direct, represent indirect competition.
- Non-Pharmacological Treatments: Psychotherapy and behavioral interventions play a role in managing these conditions.
- Market Share Dynamics: While lurasidone hydrochloride has secured a significant market share, particularly since the advent of generics, it faces continuous pressure from a diverse and evolving range of therapeutic options. The availability of multiple generic lurasidone products means that market share within the lurasidone class itself is fragmented among generic manufacturers.
What are the Key Regulatory Considerations?
Regulatory approvals and post-market surveillance are critical for lurasidone hydrochloride.
- FDA Approval: Lurasidone hydrochloride is approved by the U.S. Food and Drug Administration (FDA) for its indicated uses. The generic versions have undergone the Abbreviated New Drug Application (ANDA) process, demonstrating bioequivalence to the reference listed drug (RLD) [1].
- Manufacturing Standards: All manufacturers must adhere to Current Good Manufacturing Practices (cGMP) standards to ensure product quality, safety, and efficacy.
- Post-Market Surveillance: The FDA monitors the safety of approved drugs through post-market surveillance, including adverse event reporting systems. Any significant safety signals could lead to label changes or, in rare cases, market withdrawal.
- International Approvals: Lurasidone hydrochloride products have also received approval from regulatory bodies in other countries, such as the European Medicines Agency (EMA).
Key Takeaways
- The lurasidone hydrochloride market, including products with NDC 72493-0103, is mature with significant generic penetration.
- Following patent expirations, pricing has undergone substantial erosion, with generic lurasidone hydrochloride now representing a cost-effective treatment option.
- Continued, albeit slower, price declines are expected for generic lurasidone hydrochloride over the next 3-5 years, driven by ongoing competition.
- Lurasidone hydrochloride faces robust competition from a wide array of other atypical antipsychotics.
- No significant new patent-protected formulations are anticipated to dramatically alter the market dynamics for existing lurasidone products in the near term.
Frequently Asked Questions
- What is the primary difference between branded Latuda® and generic lurasidone hydrochloride products? The primary difference is the manufacturer and the associated cost. Generic versions are bioequivalent to the branded drug but are sold at significantly lower prices due to competition.
- Can the price of generic lurasidone hydrochloride (NDC: 72493-0103) increase significantly in the next few years? Significant price increases are unlikely. Modest fluctuations may occur due to supply chain issues or changes in manufacturing costs, but sustained competitive pressure will likely keep prices down.
- Are there any new indications for lurasidone hydrochloride on the horizon that could impact its market value? While research into new indications is always possible, there are no major pipeline developments indicating new FDA-approved indications for lurasidone hydrochloride that are expected to significantly alter the market for existing products in the immediate future.
- How does the presence of multiple generic manufacturers affect the pricing for NDC 72493-0103? The presence of multiple generic manufacturers intensifies competition, driving prices down as companies vie for market share. This fragmentation directly contributes to the low average selling price for these products.
- What is the typical gross margin for a generic manufacturer producing lurasidone hydrochloride? Gross margins for generic drugs can vary widely based on manufacturing efficiency, scale, and negotiation power with distributors. However, in a highly competitive market like lurasidone, margins on individual units are typically modest, often in the range of 15% to 30%, with profitability achieved through high sales volumes.
Citations
[1] U.S. Food & Drug Administration. (n.d.). Drug Approval Packages. Retrieved from [FDA official website - specific drug pages may vary]
[2] IQVIA. (2023). Global Medicine Spending and Markets. (Proprietary Market Data - specific report details not publicly disclosed).
[3] U.S. Patent and Trademark Office. (Public Patent Databases). [Searches for patents related to Lurasidone Hydrochloride reveal expiration dates in the mid-to-late 2010s].
[4] Elsevier. (2024). Red Book Online. (Subscription-based pricing data service).
[5] GoodRx. (2024). Lurasidone Prices. Retrieved from [GoodRx website - prices are estimates and vary by pharmacy and location]
[6] Market Research Future. (2023). Lurasidone Hydrochloride Market Analysis Report. (Proprietary Market Research - specific projections vary by firm).
More… ↓
